Vyome Holdings (HIND) Net Equity Issued and Repurchased (2018 - 2026)
Vyome Holdings (HIND) posted quarterly Net Equity Issued and Repurchased of $5.3 million for Q1 2026, up 11.16% year-over-year from $4.8 million in Q1 2025, and up 312.34% quarter-over-quarter from $1.3 million in Q4 2025.
Vyome Holdings (HIND) Net Equity Issued and Repurchased (2018 - 2026) Analysis & Trends
Vyome Holdings' Net Equity Issued and Repurchased history runs 6 years deep, the most recent figure standing at $5.3 million for Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased rose 11.16% year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $11.1 million (down 30.69% YoY), while the FY2025 annual figure was $1.3 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased for Q1 2026 stood at $5.3 million, up from $1.3 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $10.2 million in Q1 2023, with the low at $679633.0 in Q3 2025.
- The 4-year median for Net Equity Issued and Repurchased is $3.8 million (2025), against an average of $4.4 million.
- The sharpest annual moves came in 2025 and 2026: Net Equity Issued and Repurchased sank 53.35% in 2025, then climbed 11.16% in 2026.
- Vyome Holdings' Net Equity Issued and Repurchased stood at $987000.0 in 2023, then soared by 933.43% to $10.2 million in 2024, then slumped by 87.42% to $1.3 million in 2025, then jumped by 312.34% to $5.3 million in 2026.
- Business Quant data shows HIND's Net Equity Issued and Repurchased at $5.3 million in Q1 2026, $1.3 million in Q4 2025, and $679633.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | -3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,000.00 |
| Jun 30, 2026 | -3,000.00 |
| Mar 31, 2026 | 5.29 Mn |
| Mar 31, 2026 | 5.29 Mn |
| Dec 31, 2025 | 1.28 Mn |
| Dec 31, 2025 | 1.28 Mn |
| Sep 30, 2025 | 679,633.00 |
| Sep 30, 2025 | 679,633.00 |
| Jun 30, 2025 | 3.80 Mn |
| Jun 30, 2025 | 3.80 Mn |
| Mar 31, 2025 | 4.76 Mn |
| Mar 31, 2025 | 4.76 Mn |
| Mar 31, 2024 | 10.20 Mn |
| Mar 31, 2024 | 10.20 Mn |
| Dec 31, 2023 | 987,000.00 |
| Dec 31, 2023 | 987,000.00 |
| Jun 30, 2023 | 2.25 Mn |
| Jun 30, 2023 | 2.25 Mn |
| Mar 31, 2023 | 10.20 Mn |
| Mar 31, 2023 | 10.20 Mn |